Back to Agenda
Facilitating Access: Patient Perspectives on a Streamlined Development Approach for Treatments for Severely-Debilitating or Life-Threatening Diseases
Session Chair(s)
Judith Prescott, DVM, PhD
Executive Director, Safety Assessment, Merck & Co., Inc., United States
This forum will introduce a streamlined approach to the development of therapies to address severely-debilitating or life threatening diseases and consider the potential value of global regulatory guidance.
Learning Objective : Discuss the use of streamlined development programs to expeditiously deliver promising new treatments to patients with severely debilitating or life-threatening diseases from the patient perspective.
Speaker(s)
Judith Prescott, DVM, PhD
Executive Director, Safety Assessment, Merck & Co., Inc., United States
Proposal for Development of Pharmaceuticals for Severly-Debilitating or Life Threatening Indications
Haleh Saber, PhD
Director, Division of Hematology Oncology Toxicology, FDA, United States
Severely Debilitating or Life-Threatening Hematologic Disorders: Nonclinical Considerations
Susan Schaeffer
President and Chief Executive Officer, The Patients' Academy For Research Advocacy, United States
Perspective from The Patients' Academy For Research Advocacy
Catherine Kopil, PhD
Director, Research Partnerships, The Michael J. Fox Foundation for Parkinson's Research, United States
Panelist
Isabelle Lousada, MA
Chief Executive Officer and President, Amyloidosis Research Consortium, United States
Panelist
Have an account?